HASSELT, Belgium--(BUSINESS WIRE)--MabCure, N.V. (“MabCure”) a wholly-owned subsidiary of MabCure Inc. (OTCBB: MBCI) , a biotech company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand. The study aims to evaluate MabCure’s panel of anti-ovarian MAbs in diagnosing the presence of ovarian cancer in patients suspected of having the disease.
